Pluvicto is a therapy product that sells for around $50,000 a dose USD
Illuccix is an imaging product that sells for around $5,000 a dose USD
They are both completely different products which telix is developing a competing product called TLX591 which is around 2 years off of commercialization is successful and
80m for a quarter of Pluvicto is a flop considering the market size IMO
Best you read the thread understanding telix https://hotcopper.com.au/threads/understanding-telix.7155139/
Ann: JP Morgan Healthcare Conference and Trading Update, page-118
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.74 |
Change
0.300(1.72%) |
Mkt cap ! $5.936B | |||
| Open | High | Low | Value | Volume |
| $17.50 | $17.88 | $17.42 | $23.05M | 1.299M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3775 | $17.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.74 | 1499 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| TLX (ASX) Chart |